An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels-Reference-Cited by-同舟云学术

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Published:2015-04-07 Issue:5 Volume:262 Page:1344-1353
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Yiu Eppie M.,Tai Geneieve,Peverill Roger E.,Lee Katherine J.,Croft Kevin D.,Mori Trevor A.,Scheiber-Mojdehkar Barbara,Sturm Brigitte,Praschberger Monika,Vogel Adam P.,Rance Gary,Stephenson Sarah E. M.,Sarsero Joseph P.,Stockley Creina,Lee Chung-Yung J.,Churchyard Andrew,Evans-Galea Marguerite V.,Ryan Monique M.,Lockhart Paul J.,Corben Louise A.,Delatycki Martin B.

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-015-7719-2.pdf

Reference38 articles.

1. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M (1996) Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 335:1169–1175

2. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423–1427

3. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, Authier FJ, Durr A, Mandel JL, Vescovi A, Pandolfo M, Koenig M (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6:1771–1780

4. Marmolino D (2011) Friedreich’s ataxia: past, present and future. Brain Res Rev 67:311–330

5. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF (2008) Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers. Mol Genet Metab 94:491–497

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New and Emerging Drug and Gene Therapies for Friedreich Ataxia;CNS Drugs;2024-08-08

2. Emerging therapies in hereditary ataxias;Trends in Molecular Medicine;2024-08

3. The importance of synthetic pharmacotherapy for recessive cerebellar ataxias;Expert Review of Neurotherapeutics;2024-07-09

4. Diffusion-Weighted Magnetic Resonance Imaging (dMRI) and Cochlear Implant Outcomes in Axonal Auditory Neuropathy: A Case Report;Journal of Clinical Medicine;2024-05-24

5. Recent Advances in the Treatment Strategies of Friedreich’s Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms;Current Pharmaceutical Design;2024-05